Trainee Spotlight featuring Kieran Adam, graduate student in Dario Vignali's lab.

🔦 Introducing our new Trainee and Staff Spotlight series! 🔦 First up: Kieran Adam, @Pitt_PMI grad student in Dario Vignali's @vignalilab.bsky.social lab, who studies the inhibitory receptor #LAG3 and how it can be targeted to improve immunotherapy efficacy. www.immunology.pitt.edu/news/trainee...

Graphic with headshot of Nicole Mihalik, postdoctoral associate in Dario Vignali's lab at the University of Pittsburgh Department of Immunology, announcing her new F32 training grant from the National Cancer Institute for her project titled "Relative and synergistic contributions of PD1 and LAG3 on CD4+ T conventional cells in cancer."

Congratulations to Nicole Mihalik, postdoc in the @vignalilab.bsky.social, for being awarded an F32 fellowship from the National Cancer Institute to investigate how #PD1 and #LAG3 regulate CD4+ #Tcell exhaustion in #cancer! Read more: buff.ly/WM8Ajt3

Decoding LAG3 activation: ubiquitination liberates immunosuppressive motif to license checkpoint function - Molecular Biomedicine Molecular Biomedicine -

#Highlight
Decoding LAG3 activation: ubiquitination liberates immunosuppressive motif to license checkpoint function doi.org/10.1186/s435...

The highlighted article in Cell @cellpress.bsky.social ：https://doi.org/10.1016/j.cell.2025.02.014

#LAG3 #TCRsignaling #ubiquitination #checkpoint

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial - Nature Medicine In the randomized phase 1b/2 Morpheus-Melanoma trial evaluating various neoadjuvant immune checkpoint inhibitor regimens in patients with resectable stage III melanoma, tobemstomig, an anti-PD-1/anti-LAG-3 bispecific antibody, showed the highest pathologic response rate with a better safety profile than the standard treatment approach of ipilimumab plus nivolumab.

💪#Power of #bispecifics in #cancer #patient #treatment?
✴️Anti-#PD1 x #LAG3 #bispecific had similar anti-#tumour #efficacy vs anti-#PD1/anti-#CTLA4 #combo but with better #safety #profile
⏲️Time to move #multispecifics vs #macrophages where #monos failed!
www.nature.com/articles/s41...

Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs This study uncovers the molecular mechanism of LAG3 activation upon ligand engagement and its regulation by non-degradative polyubiquitination within the tumor microenvironment. The findings highlight...

This week #JournalClub @labsoap.bsky.social #LAG3 #immunecheckpoint @cellpress.bsky.social www.cell.com/cell/fulltex...

Unlocking LAG3: Ubiquitin’s unexpected role The inhibitory receptor LAG3 is the target of the FDA-approved mAb relatlimab, but its mechanism of signaling is not well understood. In this issue of Cell, Jiang et al. demonstrate that ubiquitinatio...

🔓 New #CellPreview by Prof. Kai W. Wucherpfennig @harvard.edu highlights our work on LAG3!

Key take:
• Cbl-mediated, non-degradative poly-ubiquitination at K498 unlocks LAG3 signaling
• Marks TILs that respond to PD-1/LAG3 combo

#LAG3 #Immunotherapy #PD1 #TCell
www.cell.com/cell/fulltex...

Crystal structure of the human LAG-3–HLA-DR1–peptide complex The structural basis of how the immune checkpoint molecule LAG-3 binds peptide HLA-II is resolved.

This week in #Science #Immunology: Jan Petersen, Jamie Rossjohn, & colleagues have solved the #CrystalStructure of human #LAG3 – #HLADR1 – #peptide complex, a major target of #ImmuneCheckpoint #therapy!

Prof Hussein Tawbi #melanoma #Immunotherapy guru @mdanderson.bsky.social talks evolution of first line therapy. Highlights #LAG3 & lays out summary of what may be optimal for first line therapy & what looks promising/ #PD1 #CTLA4 #nivo #Ipi @bmsnews.bsky.social
#BRIDGE2024 @sitcancer.bsky.social

Prof. Robert Ferris #headandneckcancer #surgical #oncologist Guru @ UNC talks about #neoadjuvant #immunotherapy/ exciting data/do not post/interesting #LAG3 biomarker data/ #nivo + #Rela / #BRIDGE2024 @sitcancer.bsky.social / great discussion/Cites Drs Bell, Leidner & Crittenden #FinishCancer

Dr Jean-Francois Pouliot #immunotherapy expert @regeneron.com talks #neoadjuvant + #adjuvant #LAG3 + #PD1 for respectable early stage #NSCLC /question: based on #ODAC @fda.gov contributions of components #BRIDGE2024 @sitcancer.bsky.social @alkpositiveuk.bsky.social @lungcancerresearch.bsky.social

💥 #Cancer #Vaccines in combo IO are #HOT!! Wasn’t on Bsky 11/8 so posting now/@ #SITC2024 we reported tripling of response rate & progression-free survival #PFS in #HNSCC + COOL #TCR #LAG3 & #DarkMatter data @patrickhwumd.bsky.social @chrystalpaulos.bsky.social www.einpresswire.com/article/7584...